Cargando…
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Ja...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368811/ https://www.ncbi.nlm.nih.gov/pubmed/30736835 http://dx.doi.org/10.1186/s13023-019-1000-1 |
_version_ | 1783394069635923968 |
---|---|
author | Waddington-Cruz, Márcia Schmidt, Hartmut Botteman, Marc F. Carter, John A. Stewart, Michelle Hopps, Markay Fallet, Shari Amass, Leslie |
author_facet | Waddington-Cruz, Márcia Schmidt, Hartmut Botteman, Marc F. Carter, John A. Stewart, Michelle Hopps, Markay Fallet, Shari Amass, Leslie |
author_sort | Waddington-Cruz, Márcia |
collection | PubMed |
description | We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden). East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors. The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%). Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]). Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4). The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN. Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%). Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1000-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6368811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63688112019-02-15 Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series Waddington-Cruz, Márcia Schmidt, Hartmut Botteman, Marc F. Carter, John A. Stewart, Michelle Hopps, Markay Fallet, Shari Amass, Leslie Orphanet J Rare Dis Review We describe 542 cases of symptomatic hereditary transthyretin amyloid polyneuropathy (ATTR-PN) identified through a review of the literature published between 2005 and 2016. Approximately 18% of the cases were from countries where ATTR-PN is traditionally considered to be endemic (i.e., Portugal, Japan, and Sweden). East Asia (Japan, China, Taiwan, and South Korea) contributed a sizeable combined proportion (37.0%, n = 200) with Japan (n = 92) and China (n = 71) being the primary contributors. The most common genotypes among the 65 genotypes represented in the sample were Val30Met (47.6%), Ser77Tyr (10%), Ala97Ser (6.5%), and Phe64Leu (4.4%). Cases with genotypes other than the aforementioned four had the lowest ages at onset (mean 49.2 [standard deviation {SD} 21.0; inter-quartile range {IQR}14.7]) and diagnosis (mean 53.4 [SD 21.0; IQR 14.7]). Conversely, Phe64Leu mean age of onset was 67.5 (SD 8.8; IQR 5.2) and mean age of diagnosis was 71.3 (SD 8.8; IQR 5.4). The prevalence of upper and lower limb involvement at the time of diagnosis (67 and 41%) observed across all cases is consistent with the typical presentation of ATTR-PN. Other notable findings at the time of diagnosis included a high rate of impotence among the Ala97Ser cases versus all others (67% vs. 21%) and a high rate of non-motor visual symptoms (i.e., visual opacities and glaucoma) in the Ser77Tyr cases versus all others (93% vs. 16%). Though comparisons were made descriptively and were hindered by inconsistency of reporting across the cases, these findings support the notion that ATTR-PN is a more phenotypically and geographically variable disease than is typically considered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-019-1000-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-08 /pmc/articles/PMC6368811/ /pubmed/30736835 http://dx.doi.org/10.1186/s13023-019-1000-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Waddington-Cruz, Márcia Schmidt, Hartmut Botteman, Marc F. Carter, John A. Stewart, Michelle Hopps, Markay Fallet, Shari Amass, Leslie Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title | Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title_full | Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title_fullStr | Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title_full_unstemmed | Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title_short | Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
title_sort | epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368811/ https://www.ncbi.nlm.nih.gov/pubmed/30736835 http://dx.doi.org/10.1186/s13023-019-1000-1 |
work_keys_str_mv | AT waddingtoncruzmarcia epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT schmidthartmut epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT bottemanmarcf epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT carterjohna epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT stewartmichelle epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT hoppsmarkay epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT falletshari epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries AT amassleslie epidemiologicalandclinicalcharacteristicsofsymptomatichereditarytransthyretinamyloidpolyneuropathyaglobalcaseseries |